Katrine Fladeland Iversen
Overview
Explore the profile of Katrine Fladeland Iversen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
21
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Iversen K
Basic Clin Pharmacol Toxicol
. 2024 Aug;
135(4):401-408.
PMID: 39183578
Multiple myeloma (MM) is an incurable cancer in the bone marrow. The treatment of MM has developed significantly during the last 20 years, which has resulted in increased survival. Daratumumab...
2.
Harslof M, Chanchiri I, Silkjaer T, Frolund U, Teodorescu E, Nielsen K, et al.
EJHaem
. 2024 Apr;
5(2):316-324.
PMID: 38633122
Lenalidomide maintenance (LM) has shown benefit in progression-free survival (PFS) and overall survival (OS) in clinical trials. LM is the recommended standard of care in patients with newly diagnosed multiple...
3.
Szabo A, Thorsen J, Iversen K, Levring M, Helleberg C, Hermansen E, et al.
EJHaem
. 2023 Nov;
4(4):1006-1012.
PMID: 38024635
Pomalidomide-dexamethasone (Pd) has been a standard care treatment for relapsed and refractory multiple myeloma since 2013. However, the outcomes of Pd after exposure to CD38 antibodies are not known. Here...
4.
Iversen K, Nederby L, Lund T, Plesner T
Clin Hematol Int
. 2022 Sep;
4(3):107-116.
PMID: 36131131
Multiple myeloma is an incurable disease characterized by unregulated growth of malignant plasma cells in the bone marrow (BM). Tumor-induced dysfunction of T-cells may be responsible for immune evasion and...
5.
Szabo A, Thorsen J, Iversen K, Levring M, Preiss B, Helleberg C, et al.
Am J Hematol
. 2021 Dec;
97(3):E117-E120.
PMID: 34967035
No abstract available.
6.
Szabo A, Klausen T, Levring M, Preiss B, Helleberg C, Breinholt M, et al.
PLoS One
. 2021 Oct;
16(10):e0258487.
PMID: 34644367
Methods: Information of 635 patients treated with daratumumab was collected retrospectively and included lines of therapy (LOT), hematologic responses according to the International Myeloma Working Group recommendations, time to next...
7.
Szabo A, Iversen K, Rosenvinge F, Moller S, Plesner T
Clin Hematol Int
. 2021 Oct;
2(4):168-172.
PMID: 34595458
No abstract available.
8.
Szabo A, Iversen K, Moller S, Plesner T
Clin Hematol Int
. 2021 Oct;
1(4):220-228.
PMID: 34595433
In this retrospective study we reviewed the clinical course of every patient with multiple myeloma treated from 2006 to 2016 at Vejle Hospital: 303 patients with a median age of...
9.
Hojholt K, Gregersen H, Szabo A, Klausen T, Levring M, Preiss B, et al.
Hematol Oncol
. 2021 Aug;
39(4):521-528.
PMID: 34342035
Real world evidence is important since most patients cannot be included in randomized clinical trials (RCTs). In a nationwide, cohort of relapsed/refractory multiple myeloma patients treated with daratumumab (N = ...
10.